- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01159821
A Drug Interaction Study of 31001074 and Paroxetine in Healthy Volunteers
April 7, 2014 updated by: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
An Open-Label Study to Assess the Effect of CYP2D6 Inhibitor Paroxetine on the Single-Dose Pharmacokinetics of JNJ-31001074 in Healthy Subjects
The purpose of this study is to determine the concentration of 31001074 in blood samples from healthy volunteers who have been administered 31001074 and paroxetine.
Study Overview
Detailed Description
This is an open-label (both volunteer and study physician will know the identity of study treatment) pharmacokinetic study to determine the effects, if any that multiple 20-mg doses of paroxetine have on the concentration of a single dose of study drug (referred to as 31001074) in the bloodstream after paroxetine and 31001074 are administered orally (by mouth) to healthy adult volunteers.
Paroxetine is an approved drug used to treat patients with psychiatric disorders and 31001074 is a drug that is currently under development for potential uses in the treatment of patients with nervous system disorders.
Approximately 14 healthy volunteers will participate in the study for approximately 45 days (includes a screening period of up to 29 days to determine eligibility and a 16 day treatment period).
Volunteers will be required to stay overnight at the study center during the 16-day treatment period.
During the 16-day treatment period, volunteers will receive 2 doses of 31001074 and 12 doses of paroxetine.
At Screening, a blood sample will be collected from all volunteers for pharmacogenomic analysis (ie, genetic testing) to identify volunteers genetically-determined to have high activity of an enzyme (CYP2D6) that is involved in the processing of 31001074 by the body.
Additional blood samples will be obtained from volunteers at protocol-specified time points during the study to determine the concentration of 31001074 and paroxetine in plasma (the colorless portion of blood).
Safety will be evaluated during the study by monitoring adverse events (side effects) reported and findings from clinical laboratory tests, vital signs measurements, electrocardiograms (ECGs), and physical examinations performed.
In addition, volunteers will be instructed to report the occurrence of adverse events that are considered by the study physician to be serious (as defined by the protocol) for up to 30 days after the administration of the last dose of study drug.
A single dose of 31001074 will be administered on Day 1 and Day 13 (total 2 doses).
Paroxetine will be administered once daily from Days 4 through 15 (total 12 doses).
All doses, including 31001074 and paroxetine will be administered at the same time (approximately 8 am), except on Day 13, when paroxetine will be administered 30 minutes (approximately 7:30 am) before the administration of 31001074.
Study Type
Interventional
Enrollment (Actual)
14
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Kansas
-
Overland Park, Kansas, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Have a body mass index (BMI) (weight [kg]/height2 [m]2) between 18 and 30 kg/m2 (inclusive), and body weight not less than 50 kg
- Have a blood pressure after the healthy volunteer is supine [ie, lying down face up] for 5 minutes between 90 and 140 mmHg systolic, inclusive, and no higher than 90 mmHg diastolic at screening and at admission to the study center on Day -1
- If a woman, must be of nonchildbearing potential, i.e., postmenopausal (no spontaneous menses for at least 2 years) or surgically sterile
- Be a nonsmoker
Exclusion Criteria:
- Have a history of or a current medical illness that the investigator (study physician) considers to be clinically significant, a history of chronic uveitis (inflammation of the eye persisting for a long time) or any any intraocular surgery (except for cataract extraction, laser in situ keratomileusis [LASIK], or photorefractive keratectomy [PRK] procedures [ie, procedures used to reshape the cornea of the eye])
- Have clinically significant abnormal laboratory values, abnormal ECG, or a positive test for human immunodeficiency virus (HIV) 1 and 2 antibodies, hepatitis B surface antigen (HBsAg), or hepatitis C antibodies
- If a woman, be pregnant, lactating or completed last term pregnancy within 6 months before admission to study center on Day -1
- Have known allergy to heparin (agent used to prevent clotting of the blood) or history of heparin induced thrombocytopenia (low blood platelet count as a result of the medication heparin)
- Have intermediate or low activity of CYP2D6 as determined by genetic testing
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 001
31001074/paroxetine 1 tablet of 31001074 will be administered on Day 1 and Day 13.
One 20-mg paroxetine tablet will be administered once daily from Days 4 through 15
|
1 tablet of 31001074 will be administered on Day 1 and Day 13.
One 20-mg paroxetine tablet will be administered once daily from Days 4 through 15
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetic parameters (area under the plasma concentration-time curve [AUC] and the maximum plasma concentration [Cmax]) of 31001074 with and without the coadministration of paroxetine
Time Frame: 0 to 72 hours after study drug administration on Day 1 and Day 13
|
0 to 72 hours after study drug administration on Day 1 and Day 13
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The number and type of adverse events and serious adverse events reported
Time Frame: From screening (up to 29 days before study drug administration) through 30 days after Day 16 (study completion) or at the time of early withdrawal from the study
|
From screening (up to 29 days before study drug administration) through 30 days after Day 16 (study completion) or at the time of early withdrawal from the study
|
Results from clinical laboratory tests performed
Time Frame: During screening (15 to 29 days before study drug administration) through Day 16 or at the time of early withdrawal from the study
|
During screening (15 to 29 days before study drug administration) through Day 16 or at the time of early withdrawal from the study
|
Findings from electrocardiograms (ECGs) and vital signs measurements performed
Time Frame: During screening (15 to 29 days before study drug administration) through Day 16 or at the time of early withdrawal from the study
|
During screening (15 to 29 days before study drug administration) through Day 16 or at the time of early withdrawal from the study
|
Findings from physical examinations performed
Time Frame: During screening (15 to 29 days before study drug administration) and on Day 16 or at the time of early withdrawal from the study
|
During screening (15 to 29 days before study drug administration) and on Day 16 or at the time of early withdrawal from the study
|
Columbia Suicide Severity Rating Scale (C-SSRS) scores to assess severity and track suicidal events during treatment
Time Frame: During screening (15 to 29 days before study drug administration) through Day 16 or at the time of early withdrawal from the study
|
During screening (15 to 29 days before study drug administration) through Day 16 or at the time of early withdrawal from the study
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2010
Study Completion (Actual)
October 1, 2010
Study Registration Dates
First Submitted
July 8, 2010
First Submitted That Met QC Criteria
July 8, 2010
First Posted (Estimate)
July 9, 2010
Study Record Updates
Last Update Posted (Estimate)
April 8, 2014
Last Update Submitted That Met QC Criteria
April 7, 2014
Last Verified
April 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Cytochrome P-450 Enzyme Inhibitors
- Antidepressive Agents, Second-Generation
- Cytochrome P-450 CYP2D6 Inhibitors
- Paroxetine
Other Study ID Numbers
- CR017242
- 31001074ATT1014 (Other Identifier: Johnson & Johnson Pharmaceutical Research and Development, L.L.C.)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
-
King's College LondonUniversity of ReadingCompletedHealthy | Healthy AgingUnited Kingdom
Clinical Trials on 31001074/paroxetine
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedAttention Deficit Hyperactivity Disorder | Attention Deficit Disorders With Hyperactivity
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedAttention Deficit Hyperactivity Disorder | Attention Deficit Disorders With Hyperactivity
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedAttention Deficit Hyperactivity DisorderUnited States
-
Johnson & Johnson Pharmaceutical Research & Development...Withdrawn
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedHealthy | Pharmacokinetics
-
Janssen Research & Development, LLCThe Scripps Research InstituteWithdrawn
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedAttention Deficit Hyperactivity DisorderUnited States
-
GlaxoSmithKlineCompletedDepressive DisorderKorea, Republic of, Japan
-
GlaxoSmithKlineTerminatedDepressive DisorderJapan
-
GlaxoSmithKlineCompletedDepressive DisorderJapan